利塞膦酸钠治疗糖皮质激素相关骨质疏松临床疗效及安全性研究  

Study of the efficacy and safety of risedronate for the treatment of glucocorticoid-induced osteoporosis

作　　者：张彦[1] 孔晓丹[1] 袁亮[1] 王红江[1] 刘海燕[1] 隋晓燕[1] 

机构地区：[1]大连医科大学附属第二医院风湿免疫科,大连116027

出　　处：《中国骨质疏松杂志》2012年第6期552-554,582,共4页Chinese Journal of Osteoporosis

摘　　要：目的观察利塞膦酸钠治疗糖皮质激素相关骨质疏松(GIOP)的近期疗效及安全性。方法将59例糖皮质激素相关骨质疏松症随机分成2组,治疗组29例,对照组30例,2组均应用碳酸钙600mg/d口服,阿法骨化醇0.25μg每日2次口服。治疗组加利塞膦酸钠每日10mg口服,疗程6个月。各组用药前后分别检测骨密度、血钙磷、同时比较2组疼痛评分。结果治疗组治疗后骨密度、疼痛评分较治疗前均明显改善(P<0.05),对照组治疗前后无明显变化(P>0.05)。治疗组骨密度、疼痛评分较对照组明显改善(P<0.05)。二组治疗前后血钙、磷变化均无统计学差异(P>0.05)。安全性方面二组均未发现明显不良反应。结论利塞膦酸钠是治疗糖皮质激素相关骨质疏松安全有效的药物。Objective To evaluate the efficacy and safety of risedronate for the treatment of glueocorticoidinduced osteoporosis （GIOP）. Methods Fifty-nine GIOP patients were randomly divided into the two groups, 29 patients in the test group and 30 patients in the control group. Patients in two groups were all treated with calcium carbonate （1.5g/d） and alfaealcidol （0. 25ug/d）. Patients in the test group were treated with risedronate （10mg/d） for 6 months. Bone mineral density （BMD） and serum calcium and phosphorus of all patients were measured before and after the treatment. The spontaneous pain score was measured and compared. Results BMD and the spontaneous pain score of patients in the test group were significantly ameliorated after the treatment （P 〈 0.05）. There were no significant differences of BMD and the spontaneous pain score of patients in the control group （P 〉 0.05 ）. BMD and the spontaneous pain score of patients in the test group ameliorated more obvious than those of the control group （P 〈 0. 05 ）. The changes of serum level of calcium and phosphorus had no difference between two groups before and after the treatment （P 〉 0.05）. There was no obvious side-effect in two groups. Conclusion Risedronate is a safe and effective drug for the treatment of glueoeorticoid-indueed osteoporosis

关 键 词：利塞膦酸钠 糖皮质激素 骨质疏松症 

分 类 号：R589.9[医药卫生—内分泌]